Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-cash Items (2016 - 2023)

Historic Non-cash Items for Editas Medicine (EDIT) over the last 9 years, with Q2 2023 value amounting to $2.6 million.

  • Editas Medicine's Non-cash Items fell 9975.85% to $2.6 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.6 million, marking a year-over-year decrease of 9975.85%. This contributed to the annual value of $2.0 million for FY2022, which is 4045.82% up from last year.
  • Per Editas Medicine's latest filing, its Non-cash Items stood at $2.6 million for Q2 2023, which was down 9975.85% from $2.2 million recorded in Q1 2023.
  • In the past 5 years, Editas Medicine's Non-cash Items registered a high of $5.1 billion during Q4 2021, and its lowest value of $1.3 million during Q2 2021.
  • Over the past 5 years, Editas Medicine's median Non-cash Items value was $11.0 million (recorded in 2020), while the average stood at $577.0 million.
  • The largest annual percentage gain for Editas Medicine's Non-cash Items in the last 5 years was 8408225.69% (2022), contrasted with its biggest fall of 9995.97% (2022).
  • Quarter analysis of 5 years shows Editas Medicine's Non-cash Items stood at $26.1 million in 2019, then surged by 543.28% to $167.6 million in 2020, then skyrocketed by 2913.88% to $5.1 billion in 2021, then tumbled by 99.96% to $2.0 million in 2022, then grew by 25.24% to $2.6 million in 2023.
  • Its Non-cash Items was $2.6 million in Q2 2023, compared to $2.2 million in Q1 2023 and $2.0 million in Q4 2022.